AstraZeneca's Lokelma therapy for high potassium levels in the blood (hyperkalaemia) should see much wider usage by the NHS after becoming one of the first medicines to be assessed under NICE's raised ...

While CSL’s blood plasma products may avoid the levy, the new tariffs put pressure on the Albanese government to do a deal to ...

ROCKVILLE, Md., April 13, 2026 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) announced today its 2026 Class of Corporate Members who serve as strategic partners in AKF's Corporate Membership ...

Australia will not be strong-armed to pay more for medicines because of tariffs and higher prices in the US, Health Minister ...

Trade officials are “disappointed” the United States has slapped a 100 per cent branded pharmaceutical tariff on Australia, ...

Observational data suggest apixaban leads to fewer thromboembolic events but higher bleeding risk, highlighting the need for ...

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value — creating a potentially big opportunity for investors. The post GSK’s share price is under £22, but ...

Canada’s patented drug industry has established a task force with the federal government to prepare for coming trade talks ...

Continued FDA approval of iptacopan was contingent on 2-year trial data ...

Almirall is in talks with "dozens" of companies from China to license rights to medicines for other markets, CEO Carlos ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...